Article 3 min read

New Jersey’s 2026 NOL Program: Turn Unused Tax Attributes Into Working Capital

Ray Jabagjorian
Ray Jabagjorian

The New Jersey Economic Development Authority (NJEDA) will open the application window for the 2026 Technology Business Tax Certificate Transfer Program (the “NOL Program”) on May 1, 2026, with submissions due no later than June 30, 2026. For emerging and growth stage technology and biotechnology companies, this long standing incentive continues to be one of the most valuable sources for companies looking to monetize unused tax attributes.

The NOL Program allows qualified companies to sell a portion of their net operating losses (NOLs) and unused R&D tax credits to unrelated, profitable New Jersey corporations. This program enables businesses that are often pre revenue or pre profit to convert tax assets into immediate working capital to support R&D, hiring, and expansion.

With more than $75 million available annually, including $15 million set aside for companies located in Innovation Zones, Opportunity Zones, or certified as minority or woman owned, the program remains a cornerstone of New Jersey’s strategy to strengthen its innovation economy.

life-sciences-tax-credit-nol-nj-program-fifty

Key Benefits

Approved applicants may sell their NOLs and R&D tax credits for at least 80% of their value and are eligible to receive up to $20 million in lifetime benefits. This funding can be used for:

  • Working capital
  • Research and development activities
  • Equipment purchases
  • Facility build out or expansion
  • Other eligible operational expenditures

Eligibility Criteria

To participate in the NOL Program, companies must meet several statutory and administrative requirements. Key criteria include:

  • Industry Requirement: The business must be a technology or biotechnology company whose primary activity involves a scientific process, product, or service.
  • Intellectual Property: Applicants must own, have filed for, or be licensed to use protected proprietary intellectual property (patents or registered copyrights).
  • Financial Position: The company must have no positive net operating income in either of its two most recent full year GAAP financial statements. This requirement also applies to parent companies and consolidated groups.
  • Employee Thresholds:
    • 1–224 total U.S. employees (including subsidiaries)
    • Minimum New Jersey full time employees based on company age:
      • 1 employee if <3 years old
      • 5 employees if 3–5 years old
      • 10 employees if >5 years old
  • Financial Statements: The two most recent full year financial statements must be compiled, reviewed, or audited by an independent CPA firm.
  • Ongoing Compliance: Eligibility must be maintained both at application and at benefit closing.

Fees

Companies should plan for the following non-refundable program fees:

  • Application Fee: $1,000
  • Approval Fee: 1% of the tax benefit award (capped at $20,000). The application fee is credited toward this amount.

Application Timeline and Process

The 2026 application cycle will run as follows:

  • Opening Date: May 1, 2026
  • Submission Deadline: June 30, 2026

Takeaway

For New Jersey based technology and biotechnology companies, the NOL Program remains a powerful tool for transforming tax attributes into immediate, non dilutive capital. With the 2026 application window opening on May 1, now is the time for companies to evaluate eligibility, prepare financial documentation, and consider how NOL monetization can support their growth and innovation plans.

Withum plus signs

Have Questions or Need Guidance?

For more information on this topic, please contact a member of our team.

Contact Us

Related Insights

Read more
Hand holding laboratory pipette with glowing digital network connections representing scientific research and biotechnology innovation in modern lab setting.
Maximizing Innovation Incentives: How the Orphan Drug Credit Can Outperform the R&D Tax Credit

The Orphan Drug Credit (ODC) is a powerful federal tax incentive designed to encourage the development of treatments for rare diseases, generally defined as conditions affecting fewer than 200,000 individuals in the United States. For biotechnology and pharmaceutical companies advancing therapies through clinical trials, the ODC can deliver a significantly enhanced tax benefit compared to…

Read more
Tax Planning Concept: Businessman Arranging Wooden Blocks with Financial Icons and TAX Text Representing Corporate Finance and Growth Strategy
Why Global Structuring and Transfer Pricing Matter for Life Sciences Companies 

The life sciences industry is characterized by high-value intellectual property (“IP”), extensive research and development (R&D), complex regulatory environments, and global supply chains. Life sciences companies are increasingly global from day one where R&D is performed in one country, clinical trials in others, IP held centrally, and manufacturing and commercialization is performed elsewhere. These unique attributes create opportunity, but it also creates tax risk if global structuring and transfer pricing are not…

Read more
Professionals explore complex data analytics displayed on digital tablet
Savvy Massachusetts Companies Receiving Outside Financing Should Consider This Tax Planning Opportunity Before Year-End

Massachusetts corporations receiving large cash infusions from equity investors may be surprised to find that the mere act of depositing the cash into their bank account can trigger thousands of dollars in excise taxes, whether they generate taxable income or not. Massachusetts Security Corporations (“MSCs”) can be used to solve this problem. How Can My…